推荐产品
等级
pharmaceutical primary standard
API类
triflusal
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
格式
neat
储存温度
2-8°C
InChI
1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)
InChI key
RMWVZGDJPAKBDE-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Triflusal EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action. It is an irreversible inhibitor of COX-1 inhibiting thromboxane A2, preventing aggregation; it preserves vascular prostacyclin, thus promoting anti-aggregant effect. Triflusal blocks phosphodiesterase leading to an increase in cAMP levels promoting anti-aggregant effect due to inhibition of calcium mobilization.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语:
Warning
危险分类
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
靶器官
Respiratory system
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Triflusal: an old drug in modern antiplatelet therapy. Review of its action, use, safety and effectiveness.
Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese, 50(3), 199-207 (2009-05-26)
Drugs, 55(6), 823-833 (1998-06-09)
Triflusal is an antiplatelet agent structurally related to the salicylate group of compounds, but it is not derived from aspirin (acetylsalicylic acid). Platelet antiaggregant properties of triflusal and its active 3-hydroxy-4-trifluoro-methylbenzoic acid metabolite are primarily mediated by specific inhibition of
The Cochrane database of systematic reviews, (3)(3), CD004296-CD004296 (2005-07-22)
Aspirin is the standard treatment for secondary prevention of stroke and other vascular events. Several studies suggest that triflusal may have a better safety profile. To determine in people at high risk of vascular events whether triflusal is an effective
Revista de neurologia, 27(160), 951-955 (1999-02-10)
Different studies have shown that aspirin (AAS), in low doses, may lead to a considerable frequency of hemorrhagic complications when used in the long term. We compare the long-term occurrence of hemorrhagic complications with low doses of AAS and high
Drugs, 66(5), 671-692 (2006-04-20)
Triflusal (Aflen, Disgren, Tecnosal, Triflux) is a novel platelet antiaggregant with structural similarities to salicylates, but which is not derived from aspirin. It has similar efficacy to aspirin in patients with cerebral or myocardial infarction, but has a reduced risk
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门